The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / International Approvals for Guselkumab & Anakinra; Plus Adalimumab Biosimilar in Europe

International Approvals for Guselkumab & Anakinra; Plus Adalimumab Biosimilar in Europe

April 30, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Japan Approves Guselkumab
On April 6, Japan’s Ministry of Health, Labor and Welfare approved the use of guselkumab (Tremfya) to treat three forms of psoriasis: erythrodermic, plaque and pustular. Additionally, the approval included the treatment of patients with moderate to severe psoriatic arthritis for whom other existing treatments have failed.1

You Might Also Like
  • Guselkumab May Best Adalimumab for Psoriasis on the Scalp, Palms & Soles
  • Adalimumab-atto, Biosimilar to Humira, Receives FDA Approval
  • FDA Approves Adalimumab-atto, a Biosimilar of Humira
Also By This Author
  • European Commission Approves Subcutaneous Belimumab for SLE; FDA Safety Alert for Febuxostat

The agent is already approved in the U.S., Australia, Canada, Brazil and the E.U. This approval is the first for guselkumab in Asia.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

E.U. Approves Anakinra for Still’s Disease
In the E.U., anakinra (Kineret) now includes the indication for treating Still’s disease, including systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD). These indications are extensions of anakinra’s label and apply to all 28 EU member states.2

Additional labeling now notes anakinra is indicated for adults, adolescents, children and infants age 8 months and older with a body weight of 10 kg or more for the treatment of Still’s disease with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids. Anakinra can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying anti-rheumatic drugs (DMARDs).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

This approval was based on data from clinical trials, scientific literature and published meta-analyses for more than 400 patients with Still’s disease. These data show the efficacy of anakinra in both adult and pediatric patients with Still’s disease, with most patients achieving remission, as well as the improvement of Still’s disease signs and symptoms.

Mylan Acquires License to Commercialize Adalimumab Biosimilar
Mylan is partnering with Fujifilm Kyowa Kirin Biologics Co. Ltd. to commercialize a biosimilar to adalimumab (Humira) in Europe. On May 18, 2017, the European Medicines Agency (EMA) accepted for review the marketing authorization application for this proposed biosimilar. The companies expect to receive a decision from EMA in the second half of 2018.3


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. MorphoSys AG. News release: MorphoSys announces approval of Tremfya (guselkumab) for the treatment of moderate to severe forms of psoriasis and psoriatic arthritis in Japan. 2018 Apr 6.
  2. Sobi. News release: Kineret (anakinra) approved in the EU for the treatment of Still’s disease. 2018 Apr 11.
  3. Mylan. News release: Mylan partners with Fujifilm Kyowa Kirin Biologics to commercialize biosimilar to Humira (adalimumab). 2018 Apr 11.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, adult Still's Disease, anakinra, erythrodermic psoriasis, guselkumab, Japan, plaque psoriasis, Psoriasis, pustular psoriasis

You Might Also Like:
  • Guselkumab May Best Adalimumab for Psoriasis on the Scalp, Palms & Soles
  • Adalimumab-atto, Biosimilar to Humira, Receives FDA Approval
  • FDA Approves Adalimumab-atto, a Biosimilar of Humira
  • Biosimilar Update: ACR Says FDA Draft Guidance Is Promising & Biosimilar to Humira (Adalimumab) Enters Regulatory Review

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)